Myriad Genetics Inc (MYGN)
Debt-to-equity ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 701,100 | 731,700 | 740,500 | 760,000 | 783,200 | 683,400 | 735,200 | 835,200 | 885,800 | 916,600 | 947,400 | 950,100 | 967,800 | 968,600 | 902,500 | 875,200 | 879,900 | 909,300 | 918,200 | 967,200 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $701,100K
= 0.00
The debt-to-equity ratio of Myriad Genetics Inc has consistently been 0.00 for each reporting period from March 31, 2020, to December 31, 2024. This indicates that the company has not been using debt to finance its operations during this time period, as its debt level is either negligible or non-existent in relation to its equity. A low or zero debt-to-equity ratio is generally considered favorable as it suggests lower financial risk and greater financial stability. Myriad Genetics Inc's consistent zero debt-to-equity ratio may suggest a conservative capital structure and prudent financial management practices.
Peer comparison
Dec 31, 2024